This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|June 2, 2014
OptiDose Technology
Catalent's OSDrC OptiDose enables the design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement within the tablet.
Advertisement
OptiDose Technology
Catalent’s OSDrC® OptiDose™ enables design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing processes. This expands tableting capabilities in many areas that differentiate beyond existing technologies.
OptiDose technology provides the flexibility to design single or multiple API in a single tablet, with different release profiles. In addition to shown improvement in mass variability between layers, OptiDose also offers tablet design to minimize cross-layer interaction of API and improved product stability.
One of the more recognized approaches for developing high quality controlled release formulations, Wurster fluid bed technology is a bottom-spray approach, where a coating medium is sprayed onto the particle. Compared to alternative technologies, it produces a more consistent coating for powders, granules, pellets, and micro-tablets, with higher quality controlled release product due to more predictable residence time within the coating zone.
Catalent recently invested in major capacity expansions at its Schorndorf, Germany; Somerset, NJ; and Winchester, KY, facilities to increase fluid bed capacity and capabilities to meet growing customer demand.
Company name: Catalent Pharma Solutions
Website:
E-mail: [email protected]
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement